RIVAROXABAN STADA 15mg+20mg tablets medication leaflet

B01AF01 • rivaroxaban • Blood and blood forming organs | Antithrombotic agents | Direct factor xa inhibitors

Rivaroxaban is a direct oral anticoagulant that inhibits factor Xa, an essential enzyme in the coagulation cascade. It is used for the prevention and treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and to reduce the risk of stroke in patients with non-valvular atrial fibrillation.

Rivaroxaban is administered orally, usually once daily, and has the advantage of not requiring regular INR (international normalized ratio) monitoring, unlike traditional anticoagulants such as warfarin. It is also indicated for the prevention of thromboembolic events following major orthopedic surgeries, such as hip or knee replacement.

Common side effects include bleeding, anemia, nausea, and dizziness. In rare cases, severe bleeding or allergic reactions may occur. It is important for patients to inform their healthcare provider about any other medications or supplements they are taking, as interactions may increase the risk of bleeding.

Rivaroxaban is a modern and effective option for the prevention and treatment of thromboembolic events, offering improved safety and convenience for patients.